NIH Adaptive COVID-19 Treatment Trial

NIH Adaptive COVID-19 Treatment Trial
Name	Adaptive COVID-19 Treatment Trial
Acronym	ACTT
Sponsor	National Institutes of Health
Location	United States
Phase	IV
Status	Completed

NIH Adaptive COVID-19 Treatment Trial was a multicenter, randomized, double-blind platform trial initiated to evaluate therapeutics for COVID-19 during the SARS-CoV-2 pandemic. The trial was coordinated by the National Institute of Allergy and Infectious Diseases and conducted at sites associated with institutions such as the University of Minnesota, Massachusetts General Hospital, and Johns Hopkins Hospital. It informed practice at organizations including the World Health Organization, the Food and Drug Administration, and the Centers for Disease Control and Prevention.

Background

The trial was launched in response to the global public health emergency declared by the World Health Organization and building on prior experience from trials like the Solidarity Trial and the RECOVERY Trial. Leadership included investigators connected to the National Institute of Allergy and Infectious Diseases, whose director, Anthony Fauci, had public roles in pandemic response alongside officials from the U.S. Department of Health and Human Services and collaborations with academic centers such as Yale University, Harvard Medical School, and University of California, San Francisco. The platform design drew on adaptive methodologies previously implemented in influenza and Ebola research at institutions including the Johns Hopkins Bloomberg School of Public Health and the London School of Hygiene & Tropical Medicine.

Trial Design and Methods

ACTT used a master protocol permitting sequential addition and removal of arms, an approach informed by adaptive platform trials such as the I-SPY Trial and regulatory frameworks from the Food and Drug Administration. The coordinating center was the National Institute of Allergy and Infectious Diseases's Clinical Trials Network, with statistical design input consistent with guidance from the European Medicines Agency and analyses comparable to those used in trials at the National Cancer Institute. Randomization, blinding, and intention-to-treat analyses followed standards taught at programs like Duke University School of Medicine and Columbia University Vagelos College of Physicians and Surgeons. Data collection aligned with case report standards used in multicenter studies at the Mayo Clinic and Cleveland Clinic.

Interventions and Randomization

Initial interventions included antiviral agents and immunomodulators evaluated in parallel, with notable early investigation of remdesivir developed by Gilead Sciences and repurposed in settings similar to prior antiviral trials such as those for Ebola therapies. Other participating investigational agents came from pharmaceutical partners including AbbVie, Roche, and academic collaborators like Fred Hutchinson Cancer Center. Randomization stratification paralleled methods used in trials at Vanderbilt University Medical Center and Mount Sinai Health System, with eligibility criteria adapted from consensus documents produced by the Infectious Diseases Society of America and clinical guidance from Society of Critical Care Medicine.

Outcomes and Results

Primary endpoints measured time to recovery and clinical status at fixed intervals, using ordinal scales similar to those employed in the RECOVERY Trial and outcome frameworks from the Global Health Network. Major findings included shortened time to recovery associated with remdesivir compared to placebo, results that influenced emergency use authorizations by the Food and Drug Administration and therapeutic guidance from the World Health Organization and led to publications in journals with editorial boards like those of the New England Journal of Medicine and JAMA. Secondary analyses examined mortality, duration of hospitalization, and subsequent health resource use, with follow-up studies undertaken at centers such as Stanford University and University of Washington.

Safety and Adverse Events

Safety monitoring was overseen by an independent data and safety monitoring board with membership drawn from experts affiliated with Beth Israel Deaconess Medical Center, University of California, Los Angeles, and the Medical Research Council networks. Adverse event reporting adhered to standards used by the Food and Drug Administration and international pharmacovigilance practices coordinated with agencies like the European Medicines Agency. Reported risks included transaminase elevations and infusion-related events, with risk–benefit assessments compared to prior antiviral safety profiles from trials at Imperial College London and Karolinska Institute.

Regulatory and Ethical Considerations

Ethical review was conducted by institutional review boards at participating sites including Brigham and Women's Hospital, University of Pennsylvania Health System, and Icahn School of Medicine at Mount Sinai. Regulatory interactions involved the Food and Drug Administration for emergency use authorizations and coordination with the Office for Human Research Protections. Consent procedures were adapted for pandemic constraints following recommendations from bioethics committees at Georgetown University and guidance from the National Academy of Medicine.

Impact and Subsequent Research

ACTT results shaped clinical practice, influencing guidance from the World Health Organization, adoption in hospital protocols at systems such as Kaiser Permanente and HCA Healthcare, and spurring further trials at institutions including University College London and University of Toronto. Subsequent research included combination therapy trials, mechanistic studies at laboratories like the Broad Institute, and meta-analyses coordinated with efforts from the Cochrane Collaboration and the Global Health Network. The trial’s adaptive platform model informed later platform trials including updates to the RECOVERY Trial and pandemic preparedness initiatives at the Pan American Health Organization.

Category:Clinical trials